PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 63961

Controlled studies with bleomycin in solid tumors and lymphomas.

G Bonadonna·G Tancini·E Bajetta
View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

BleomycinCarcinoma, BronchogenicCarcinoma, Squamous CellClinical Trials as TopicDose-Response Relationship, DrugDrug Administration ScheduleDrug EvaluationDrug Therapy, CombinationEsophageal NeoplasmsFemaleHead and Neck NeoplasmsHodgkin DiseaseHumansLung NeoplasmsLymphomaMaleNeoplasmsPulmonary FibrosisTesticular NeoplasmsUterine Cervical NeoplasmsClinical TrialComparative StudyJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G Bonadonna, G Tancini, E Bajetta. 1976. Controlled studies with bleomycin in solid tumors and lymphomas.. https://pubmed.ncbi.nlm.nih.gov/63961/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1979

Oxygenated iron bleomycin. A short-lived intermediate in the reaction of ferrous bleomycin with O2.

The reaction of Fe(II) . bleomycin with O2 to yield Fe(III) . bleomycin has been resolved into two kinetic events by stopped-flow spectrophotometry. The first event is first order with respect to both bleomycin and O2 and may be regarded as a second order reaction (k = 6.1 x 10(3) M-1s-1 at 2 degrees C). The first product has no EPR spectrum. The optical spectrum resembles those of Fe(II) . bleomycin complexes with CO, NO, and ethyl isocyanide. We propose that the first product is an Fe(II) . bleomycin . O2 complex. The second kinetic event is first order with respect to the first accumulated product (k = 0.11 s-1 at 2 degrees C) and independent of oxygen concentration. The product of this reaction is indistinguishable from Fe(III) . bleomycin by optical and EPR spectroscopy.

Bleomycin↗